Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.